Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. Home

Expert Video Report on Novel Drugs for HER2+ Advanced Breast Cancer: Focus on Brain Metastases

Reporting remotely on findings presented at ESMO Breast Cancer Virtual Meeting 2020, Guy Jerusalem comments on practice changing studies in pretreated patients with HER2+ advanced breast cancer, focusing on the important risk of brain metastasis in this population.

He firstly showed the results from the DESTINY-Breast01 trial subgroup analysis of patients with an history of CNS metastasis, treated with trastuzumab deruxtecan. Secondly, he discusses the results from the HER2CLIMB trial testing the addition of a tyrosine kinase inhibitor, tucatinib to trastuzumab plus capecitabine combined therapy, in HER2+ metastatic breast cancer patients with or without CNS metastasis at study inclusion.

Abstracts:

  • 138O - CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses
  • 137O - Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.